Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYL080
MIFTS: 27

Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Categories: Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

MalaCards integrated aliases for Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

Name: Myalgic Encephalomyelitis/chronic Fatigue Syndrome 52
Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis 52
Systemic Exertion Intolerance Disease 52
Me/cfs 52

Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
NIH Rare Diseases : 52 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an umbrella term that includes both myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS). It is a serious, chronic and complex disease that affects many systems of the body and can profoundly impact daily activities. The main symptom is disabling fatigue that does not improve with rest and lasts at least 6 months. Fatigue may get worse after activity, which is known as post-exertional malaise. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes . ME/CFS generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The exact cause is not known, but symptoms may be triggered by an infection. Diagnosis can be difficult as there are no specific laboratory tests and the symptoms are common to a number of different illnesses. There is no cure or effective treatment for this condition but there are several clinical trials . While the term ME/CFS is widely used, there is still a debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome and there is no universally accepted definition. The term "systemic exertion intolerance disease" has been proposed as new term for both diseases.

MalaCards based summary : Myalgic Encephalomyelitis/chronic Fatigue Syndrome, also known as chronic fatigue syndrome/ myalgic encephalomyelitis, is related to chronic fatigue syndrome and fibromyalgia. An important gene associated with Myalgic Encephalomyelitis/chronic Fatigue Syndrome is IL16 (Interleukin 16), and among its related pathways/superpathways is Cytokine Signaling in Immune system. The drugs Antiviral Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, lymph node and brain.

Sources

Related Diseases for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

Diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 chronic fatigue syndrome 32.9 RNASEL IL7
2 fibromyalgia 10.9
3 orthostatic intolerance 10.8
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
5 autonomic dysfunction 10.7
6 irritable bowel syndrome 10.6
7 autoimmune disease 10.5
8 cytokine deficiency 10.5
9 physical disorder 10.4
10 lyme disease 10.4
11 lactic acidosis 10.4
12 sleep disorder 10.4
13 mitochondrial disorders 10.4
14 overgrowth syndrome 10.4
15 anxiety 10.4
16 endogenous depression 10.4
17 pfeiffer syndrome 10.3
18 migraine with or without aura 1 10.3
19 celiac disease 1 10.3
20 hyperlipoproteinemia, type iii 10.3
21 juvenile arthritis 10.3
22 lipoprotein quantitative trait locus 10.3
23 coenzyme q10 deficiency disease 10.3
24 sleep apnea 10.3
25 alexithymia 10.3
26 pain agnosia 10.3
27 postural orthostatic tachycardia syndrome 10.3
28 bacterial infectious disease 10.3
29 primary biliary cirrhosis 10.3
30 benign paroxysmal positional nystagmus 10.3
31 constipation 10.3
32 spondylosis 10.3
33 gastroenteritis 10.3
34 eosinophilic gastroenteritis 10.3
35 liver disease 10.3
36 neuromuscular disease 10.3
37 multiple chemical sensitivity 10.3
38 spinal stenosis 10.3
39 juvenile rheumatoid arthritis 10.3
40 mitochondrial metabolism disease 10.3
41 herpes simplex 10.3
42 nervous system disease 10.3
43 chickenpox 10.3
44 cholangitis 10.3
45 pure autonomic failure 10.3
46 systemic onset juvenile idiopathic arthritis 10.3
47 chronic pain 10.3
48 encephalopathy 10.3
49 traumatic brain injury 10.3
50 tremor 10.3

Graphical network of the top 20 diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:



Diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome
Sources

Symptoms & Phenotypes for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
Sources

Drugs & Therapeutics for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

Drugs for Myalgic Encephalomyelitis/chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antiviral Agents Phase 3
2 Anti-Infective Agents Phase 3
3 poly(I).poly(c12,U) Phase 3
4
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
5
Glycerol Approved, Investigational Phase 2 56-81-5 753
6
rituximab Approved Phase 2 174722-31-7 10201696
7
Etanercept Approved, Investigational Phase 2 185243-69-0
8 Alkylating Agents Phase 2
9 Adrenocorticotropic Hormone Phase 1, Phase 2
10 Corticotropin-Releasing Hormone Phase 1, Phase 2
11 Cola Phase 2
12 Immunoglobulins Phase 2
13 Analgesics, Non-Narcotic Phase 2
14 Gastrointestinal Agents Phase 2
15 Antibodies Phase 2
16 Immunologic Factors Phase 2
17 Analgesics Phase 2
18 Immunosuppressive Agents Phase 2
19 Antirheumatic Agents Phase 2
20 Anti-Inflammatory Agents Phase 2
21 Anti-Inflammatory Agents, Non-Steroidal Phase 2
22 Pharmaceutical Solutions Phase 1
23
Zinc Approved, Investigational 7440-66-6 32051
24
Naltrexone Approved, Investigational, Vet_approved 16590-41-3 5360515
25
Ethanol Approved 64-17-5 702
26
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
27 Antioxidants
28 Protective Agents
29 Narcotics
30 Narcotic Antagonists

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME) Completed NCT00215800 Phase 3 Ampligen
2 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months Unknown status NCT02444091 Phase 2 Cyclophosphamide
3 Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Completed NCT03613129 Phase 1, Phase 2 CT38
4 Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT Recruiting NCT03691987 Phase 2
5 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab. Terminated NCT01730495 Phase 2 Etanercept
6 Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Active, not recruiting NCT02854683 Phase 1 Normal Saline
7 New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Unknown status NCT03502044
8 Sex Differences in Exercise-related Post-exertional Malaise in ME/CFS Unknown status NCT03331419
9 ME/CFS: Activity Patterns and Autonomic Dysfunction Unknown status NCT02948556
10 Use of a Monitor in ME/CFS Unknown status NCT01908036
11 Hypermobility and Obstructions in the Craniocervical Region Among Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Completed NCT04399330
12 An Unicentric, Double-blind, Placebo Controlled, Phase IV Clinical Trial of Oral Melatonin Plus Zinc to Evaluate Relieving Self-reported Fatigue in CFS/ME Completed NCT03000777
13 Acceptance & Commitment Therapy for ME/CFS (Chronic Fatigue Syndrome) - an Open Case Trial Completed NCT03562325
14 A RCT Study on the Effect of Short and Long Cognitive Behaviour Therapy (CBT) in CFS/ME Patients Completed NCT00920777
15 Psychological Wellbeing in Adults With Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis Completed NCT02094820
16 Developing an Activity Pacing Framework for the Management of Chronic Pain/Fatigue. Stage III: Feasibility and Acceptability Studies Completed NCT03497585
17 An Initial Trial of ASARM: an Advanced Sleep and Rest Monitoring System for Treating Paediatric CFS/ME: Assessing Acceptability and Adaptation Into Current CBT Treatment Protocols Completed NCT02082730
18 A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Recruiting NCT04100915
19 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Recruiting NCT02669212
20 Assessment of Exercise Response in Chronic Fatigue Syndrome / Myalgic Encephalomyelitis. Recruiting NCT03675087
21 Probing Metabolism, Circulating Inflammatory Molecules, Extracellular Vesicles and Immune Dysregulation in Individual Immune Cells in ME/CFS Recruiting NCT04026425
22 Cardiopulmonary Exercise Testing as a Diagnostic Tool and a Quantitative Measure of Post-exertional Malaise in Myalgic Encephalopathy/Chronic Fatigue Syndrome Active, not recruiting NCT02970240
23 Defining Autoimmune Aspects of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Enrolling by invitation NCT03254823
24 Central Mechanisms of Chronic Pain and Fatigue Subtitle: Functional Imaging of Brain and Spinal Cord Enrolling by invitation NCT03075254
25 Complex Chronic Diseases Program Data Registry Enrolling by invitation NCT03409653
26 The ME-SH (Myalgic Encephalomyelitis in Stockholm-Harvard) Study: Structural Problems in Brainstem and Cervical Spine Cord in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome(ME/CFS) - a Case-control Study Not yet recruiting NCT04403854
27 The Influence of Epigenetic Modifications and Post-Exertional Malaise in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not yet recruiting NCT04378634
28 A Pilot Study for Continuous Monitoring of Physical Activity Using Activity Armbands for 6 Months: Assessment of Feasibility and Comparison to Self-reported Questionnaires Not yet recruiting NCT04195815
29 The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) Suspended NCT02965768 Naltrexone HCl
30 Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue Terminated NCT00983502

Search NIH Clinical Center for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Sources

Genetic Tests for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
Sources

Anatomical Context for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

MalaCards organs/tissues related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

40
Testes, Lymph Node, Brain, Spinal Cord, Whole Blood, T Cells, B Cells
Sources

Publications for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

Articles related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

(show top 50) (show all 386)
# Title Authors PMID Year
1
Mitochondria and immunity in chronic fatigue syndrome. 61
32470498 2020
2
Patients' experiences and effects of non-pharmacological treatment for myalgic encephalomyelitis/chronic fatigue syndrome - a scoping mixed methods review. 61
32432991 2020
3
Epidemiological and clinical factors associated with post-exertional malaise severity in patients with myalgic encephalomyelitis/chronic fatigue syndrome. 61
32571354 2020
4
Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study. 61
31970624 2020
5
The concept of 'illness without disease' impedes understanding of chronic fatigue syndrome: a response to Sharpe and Greco. 61
32482748 2020
6
Post-exertional symptoms distinguish myalgic encephalomyelitis/chronic fatigue syndrome subjects from healthy controls. 61
32568143 2020
7
Properties of measurements obtained during cardiopulmonary exercise testing in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. 61
32568145 2020
8
Research, recommendations and lived/personal experience with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 61
32568154 2020
9
Environmental accommodations for university students affected by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 61
32568151 2020
10
Clinically accessible tools for documenting the impact of orthostatic intolerance on symptoms and function in ME/CFS. 61
32568144 2020
11
Cerebral Blood Flow Is Reduced in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients During Mild Orthostatic Stress Testing: An Exploratory Study at 20 Degrees of Head-Up Tilt Testing. 61
32545797 2020
12
Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. 61
32154656 2020
13
Elevated Perceived Exertion in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Meta-analysis. 61
32555018 2020
14
Physical activity measures in patients with myalgic encephalomyelitis/chronic fatigue syndrome: correlations between peak oxygen consumption, the physical functioning scale of the SF-36 questionnaire, and the number of steps from an activity meter. 61
32513266 2020
15
Documenting disability in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 61
32568153 2020
16
Risk factors for suicide in chronic fatigue syndrome. 61
32527207 2020
17
A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors. 61
32247028 2020
18
Research update: The relation between ME/CFS disease burden and research funding in the USA. 61
32568148 2020
19
Graded exercise therapy doesn't restore the ability to work in ME/CFS. Rethinking of a Cochrane review. 61
32568149 2020
20
Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS. 61
32568152 2020
21
Fallout from the Covid-19 pandemic - should we prepare for a tsunami of post viral depression? 61
32408926 2020
22
Preliminary ICF core set for patients with myalgic encephalomyelitis/chronic fatigue syndrome in rehabilitation medicine. 61
32488281 2020
23
Unravelling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Gender-specific changes in the microRNA expression profiling in ME/CFS. 61
32291908 2020
24
A systematic review of metabolomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis/Systemic Exertion Intolerance Disease (CFS/ME/SEID). 61
32404171 2020
25
Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology. 61
32455633 2020
26
Paediatric patients with myalgic encephalomyelitis/chronic fatigue syndrome value understanding and help to move on with their lives. 61
31854020 2020
27
Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. 61
30617782 2020
28
Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
32327453 2020
29
Altered muscle membrane potential and redox status differentiates two subgroups of patients with chronic fatigue syndrome. 61
32306967 2020
30
A potential antigenic mimicry between viral and human proteins linking Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with autoimmunity: The case of HPV immunization. 61
32062027 2020
31
The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE). 61
32272608 2020
32
Can the light of immunometabolism cut through "brain fog"? 61
32039912 2020
33
Maximal handgrip strength can predict maximal physical performance in patients with chronic fatigue. 61
31986462 2020
34
Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 61
32210306 2020
35
Rethinking the Standard of Care for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
31637650 2020
36
Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. 61
31830003 2020
37
The role of low-grade inflammation in ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) - associations with symptoms. 61
31901625 2020
38
Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic еncephalomyelitis/chronic fatigue syndrome. 61
32129496 2020
39
Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
32034172 2020
40
Activation of Transposable Elements in Immune Cells of Fibromyalgia Patients. 61
32085571 2020
41
Treating medically unexplained symptoms via improving access to psychological therapy (IAPT): major limitations identified. 61
32020880 2020
42
Cell-Based Blood Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
32046336 2020
43
Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy and graded exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review. 61
31072121 2020
44
Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome. 61
31759091 2020
45
Phylogenetic tree-based microbiome association test. 61
31504188 2020
46
An Isolated Complex V Inefficiency and Dysregulated Mitochondrial Function in Immortalized Lymphocytes from ME/CFS Patients. 61
32041178 2020
47
Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids. 61
31947545 2020
48
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset. 61
32328064 2020
49
Emotional Awareness Correlated With Number of Awakenings From Polysomnography in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-A Pilot Study. 61
32273857 2020
50
Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies. 61
32296708 2020
Sources

Variations for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
Sources

Expression for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
Search GEO for disease gene expression data for Myalgic Encephalomyelitis/chronic Fatigue Syndrome.
Sources

Pathways for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

Pathways related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 12.03 VEGFA RNASEL IL7 IL16
Sources

GO Terms for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section

Biological processes related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.13 VEGFA IL7 IL16
2 induction of positive chemotaxis GO:0050930 8.62 VEGFA IL16

Molecular functions related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.96 VEGFA IL7
2 cytokine activity GO:0005125 8.8 VEGFA IL7 IL16
Sources

Sources for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....